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Background: Aberrant Hedgehog (Hh) signaling is often associated with neuroblastoma (NB), a childhood
malignancy with varying clinical outcomes due to different molecular characteristics. Inhibition of Hh signaling with
small molecule inhibitors, particularly with GANT-61, significantly suppresses NB growth. However, NB with MYCN
amplification is less sensitive to GANT-61 than those without MYCN amplification.
Methods: Autophagic process was examined in two MYCN amplified and two MYCN non-amplified NB cells treated
with GANT-61. Subsequently, chemical and genetic approaches were applied with GANT-61 together to evaluate
the role of autophagy in GANT-61 induced cell death.
Results: Here we show that GANT-61 enhanced autophagy in MYCN amplified NB cells. Both an autophagic
inhibitor 3-methyladenine (3-MA) and genetic disruption of ATG5 or ATG7 expression suppressed GANT-61 induced
autophagy and significantly increased apoptotic cell death, whereas pre-treatment with an apoptotic inhibitor,
Z-VAD-FMK, rescued GANT-61 induced cell death and had no effect on the autophagic process. In the other hand,
GANT-61 barely induced autophagy in MYCN non-amplified NB cells, but overexpression of MYCN in MYCN
non-amplified NB cells recapitulated GANT-61 induced autophagy seen in MYCN amplified NB cells, suggesting that
the level of GANT-61 induced autophagy in NB cells is related to MYCN expression level in cells.
Conclusion: Aberrant Hh signaling activation as an oncogenic driver in NB renders inhibition of Hh signaling an
effective measure to suppress NB growth. However, our data suggest that enhanced autophagy concomitant with
Hh signaling inhibition acts as a pro-survival factor to maintain cell viability, which reduces GANT-61 efficacy.
Besides, MYCN amplification is likely involved in the induction of the pro-survival autophagy. Overall, simultaneous
inhibition of both Hh signaling and autophagy could be a better way to treat MYCN amplified NB.
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NB is one of the most common solid malignant tumors in
children. It arises from neural crest element of the sympa-
thetic nervous system and usually occurs in the adrenal
medulla [1]. Nearly half neuroblastoma is classified as high-
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unless otherwise stated.Many of them are associated with MYCN oncogene ampli-
fication [2]. Although children with high-risk tumor are ag-
gressively treated with multi-modal therapy, this group still
has poor survival rate (40%-50%) [3]. Therefore, it is critical
to understand the underlying therapy-resistant mechanism
of high-risk tumor.
The Hedgehog (Hh) signaling pathway plays a crucial role
in the regulation of numerous embryonic development pro-
cesses, including neural crest proliferation, differentiation
and patterning [4]. Its signaling cascade is mainly comprised
of Hh ligands [Sonic Hedgehog (Shh), Indian Hedgehog
(Ihh) and Desert Hedgehog (Dhh)], receptors [patched
(Ptch) and smoothened (Smo)], and downstream effectorstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ectopic expression of its components are observed in several
malignancies such as medulloblastoma, basal cell carcinoma,
rhabdomyosarcoma, etc [6,7]. Inhibition of Hh signaling has
been shown to be an effective way to block cancer cell pro-
liferation and induce cell apoptosis [8,9]. Two strategies have
been used to block Hh signaling. One is to target the trans-
membrane receptor Smo with cyclopamine or SANT1
[10,11], the other is to interfere with downstream effector
Gli transcription factors with GANT-61 [12]. Given the pos-
ition of Gli in Hh signaling cascade, GANT-61 has an ad-
vantage of functioning regardless of the mechanism of Hh
signaling activation, which would be particularly useful for
treating tumors with mutations constitutively activating Hh
signaling upstream of Gli.
NB also has aberrant expression of Hh signaling compo-
nents and is susceptible to Hh signaling inhibitor [13,14].
Both cyclopamine and GANT-61 have been shown to sup-
press NB cell growth and induce apoptosis, with GANT-61
being more effective [15,16]. However, similar to the reac-
tion of NB cells to conventional chemotherapeutic drug,
MYCN amplified NB cells are also more resistant to Hh
signaling than non-MYCN amplified NB cells do.
Here we provide first evidence that GANT-61 can induce
autophagy in MYCN amplified NB cell lines. Inhibition of
autophagy increased cell death though apoptosis, suggest-
ing a pro-survival role of autophagy in MYCN amplified
NB cell lines. However, inhibition of apoptosis did not
change the level of autophagy, although it rescued cell via-
bility. It indicates that induction of autophagy may be an in-
trinsic property of GANT-61 for treating MYCN amplified
NB cells. Furthermore, we found that the autophagic level
in MYCN non-amplified NB cells was hardly affected by
GANT-61, but MYCN overexpression in MYCN non-
amplified NB cells could enhance GANT-61 induced au-
tophagy, suggesting that MYCN amplification has a positive
role in the induction of the pro-survival autophagy. Our
data point out that a combination of GANT-61 and au-
tophagy inhibitor may be a good approach to treat high-
risk NB with MYCN amplification.
Methods
Chemicals
GANT-61, 3-Methyladenine (3-MA) and Z-VAD-FMK
were purchased from Sigma Chemical Co (St. Louis, MO,
USA). Bafilomycin A1 (BafA1) was purchased from
Cayman Chemical (Ann Arbor, MI, USA).
Cell culture
Four human neuroblastoma cell lines were used in our
research. SK-N-BE(2) cells and SH-SY5Y cells were pur-
chased from the Shanghai Institute of Cell Biology,
Chinese Academy of Sciences (Shanghai, China). NBL-
W-S and SK-N-AS cells were obtained from the StateKey Laboratory of Hematology Oncology of the Ministry of
Health, Shanghai Children’s Medical Center (Shanghai,
China). SK-N-BE(2), SH-SY5Y and NBL-W-S cells were
maintained in DMEM (Dulbecco’s Modified Eagle
Medium) with high glucose (Life Technologies, Grand
Island, NY, USA). SK-N-AS cells were cultured in DMEM
with low glucose (Life Technologies, Grand Island, NY,
USA). Both media were supplemented with 10% FBS (Life
Technologies, Grand Island, NY, USA) and 1% penicillin/
streptomycin (Sigma-Aldrich Co, St. Louis, MO). Cells
were cultured as monolayer in a humidified atmosphere
containing 5% CO2 at 37°C. When cells reached a conflu-
ence of 60-80%, media were switched to serum-free media
for drug treatment.
Fluorescence in situ hybridization
The hypotonic solution was preheated at 37°C for
30min. NB cells were precipitated, put into the pre-
warmed hypotonic solution, concentrated, fixed and
then dropped onto clean microscope slides. Slides were
allowed to dry at 56°C for 1h or at room temperature
overnight. Denaturation and hybridization were done
with LSI MYCN Probe mixture (Vysis, Downers Grove,
IL) as described by the manufacturer. DAPI II counter-
stain (Vector Laboratories, Burlingame, CA) was added
to visualize nucleus and slides were incubated in the
dark for 30 min at 4°C before imaging. Images were
taken under an upright fluorescence microscope (Olym-
pusIX51, Japan).
Cell viability assay
Cell viability and cytotoxicity was assessed by MTT [3-(4,5-
dimethylthiazol-2-yl) -2,5-diphenylterazo-lium] colorimetric
assay (Sigma, Steinheim, Germany). Cells were seeded in
96-well plates at the density of 10,000 cells in 100 μL
medium per well. MTT solution was added to the culture
medium (final concentration 500 μg/ml) and incubated for
4h at 37°C in the dark. After incubation, the supernatant
was aspirated and formazan crystals were dissolved in
100μL of DMSO at 37°C for 15 min with gentle agitation.
The absorbance value at 570 nm was read using Glo Max-
Multi Detection System (Promega, USA). Data was ana-
lyzed from three independent experiments and was
normalized to the absorbance of wells containing media
only (0%) and untreated cells (100%). IC50 values were cal-
culated from Sigmoidal dose-response curves using Sigma-
plot 10.0 software.
Protein extraction and Western blot analysis
Cells were washed twice with cold PBS (phosphate buffer
saline) and were harvested by trypsinization. For total pro-
tein isolation, cells were suspended in cell lysis buffer
(Beyotime, China) and incubated on ice for 30 min. The
suspension was collected after centrifugation at 15000 g for
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using the BCA protein assay kit (Bio-Rad, Hercules, CA,
USA) according to the manufacturer’s instruction. Fifty
microgram of proteins were denatured by boiling at 96°C
for 5 min in sample buffer (0.5M Tris-HCL, PH 6.8, 4%
Sodium dodecyl sulfate, 20% glycerol, 0.1% bromphenol
blue, 10% β-mercaptoethanol) in a ratio of 1:1. Equivalent
amounts of protein were loaded and electrophoresed in 6-
15% SDS (Sodium dodecyl sulfate)-PAGE gels. After
electrophoresis, gels were transferred to nitrocellulose
(NC) filter membranes or polyvinylidene fluoride (PVDF)
membranes. Membranes were blocked with blocking buf-
fer for 1h and then were incubated with various primary
antibodies with 1:1000 dilution for 2 h. After washing with
PBS, membranes were incubated with IRDye 800-
conjugated goat anti-rabbit IgG secondary antibody
(Rockland, USA) with 1:2000 dilution for half an hour at
room temperature. Immunoreactive bands were visualized
with a Licor Odyssey Infrared Imaging System (LI-COR
Biosciences, USA). Primary antibodies against ATG5,
ATG7, BECLIN-1, cleaved CASPASE3, AKT and phos-
phorylated AKT (ser473) and β-ACTIN were purchased
from Cell Signaling Technology, Inc. (Danvers, MA,
USA). LC3B were purchase from Novus Biologicals
(Littleton, CO, USA) and BCL-2 was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). All the
Western blot experiments were reproduced in three sep-
arate experiments
Annexin V binding assay
The Annexin V binding assay was performed according
to manufacturer’s instruction using Annexin V-FITC or
Annexin V-PE detection kit I (BD Biosciences, San
Diego, CA, USA). Cells were harvested by trypsinization
and washed twice with cold PBS. Cell pellets were re-
suspended with 100 μL binding buffer at a density of
1×105 cells per ml and incubated with 5μL of FITC or
PE-conjugated AnnexinV and 5 μL of propidium iodide
(PI) or 7-AAD for 15 min at room temperature in the
dark. 400 μl of 1X binding buffer was added to each
sample tube, and immediately the samples were analyzed
by BD FACSCanto II Flow Cytometer (BD Biosciences,
USA).
Acridine orange staining
Acridine orange (AO) (Sigma-Aldrich Co.) was used to
evaluate and quantify the formation of acid vesicular organ-
elles (AVOs) by fluorescence microscopy and flow cytome-
try. AO is an acidotropic fluorescent dye that stain DNA
and cytoplasm bright green. When protonated in the pres-
ence of acid compartments, AO fluorescences bright red.
Cells were treated with 200 nmol/l BafA1 for 30 min before
adding AO to inhibit the acidification of autophagic vacu-
oles. After incubated with the BafA1, cells were treated withAO (1 μg/ml) in serum-free medium for 15 min at 37°C.
AO was removed and fluorescent micrographs were
obtained using an inverted fluorescence microscope
(Leica DMI3000, Solms, Germany). Green (510-530 nm)
and red (650 nm) fluorescent emission from 1×104 cells
illuminated with blue (488 nm) excitation light was
measured with a BD FACSCanto II Flow Cytometer (BD
Biosciences, USA).
Monodansylcadaverine (MDC) incorporation assay
Autophagic vacuoles were also detected with MDC
staining. Cells were incubated with MDC (50 μM) in
PBS at 37°C for 10min. After incubation, cells were
washed four times with cold PBS and fixed with 3.75%
paraformaldehyde in PBS. Cells were immediately ana-
lyzed under an inverted florescence microscope (Leica
DMI3000, Solms, Germany).
Detection and quantification of endogenous LC3 vacuoles
Cells were fixed in 3.7% paraformaldehyde (PFA) in PBS
for 10 min at room temperature. Coverslips were washed
in PBS and blocked with 1% bovine serum albumin
(BSA)/PBS for 1 h. Next, cells were incubated with anti-
LC3 antibody (Diluion 1:400, Novus Biologicals, USA) in
1% BSA/PBS for 2 h at room temperature. After washing
3 times with PBS, slides were stained for 1h with goat
anti rabbit IgG-H&L Cy3 antibody (Abcam, Hongkong).
Samples were mounted with 80% glycerol and photo-
graphed under an upright florescence microscope (Leica
DM6000, Germany). Image analysis was done with
Image-Pro Plus (Media Cybernetics, USA). The average
number of fluorescent puncta in untreated NB cells is
used a basal value for AVOs in untreated conditions.
Cells with a value 5 times higher than the basal value
were scored as cells with active autophagic process. The
percentages of positive cells were determined by count-
ing a total of more than 50 cells in each sample and 3
samples were analyzed in each group.
Formation and quantification of exogenous GFP-LC3
vacuoles
Cells were transfected with GFP-LC3 plasmid (Gift of Dr.
Zhixue Liu, Institute for Nutritional Sciences, SIBS, China),
using Lipofectamine LTX (Life Technologies, USA) accord-
ing to manufacturer’s instruction. After 10uM GANT-61
treatment for 48h, cells were fixed with 4% PFA in PBS,
analyzed and photographed under an upright florescence
microscope (Leica DM6000, Germany). For quantification
of autophagic cells, the proportion of cells with punctate
green dots were determined from triplicates.
ATG5 and ATG7 shRNA knockdown
Lentiviral ATG5 and ATG7 shRNA vectors were purchased
from (Genechem, China). Lentiviral particles were produced
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vector, envelope vector PMD2.G and packaging vectors
Δ8.74 into 293FT cells (the molar ratio of plasmids is
2:3:3). Supernatant with viral particle was collected 48 h
after transfection. Viral transduction was facilitated with
8μg/ml polybrene. shRNA sequences listed below: ATG5:
5′-TTCATGGAATTGAGCCAAT-3′; ATG7: 5′-TTTGG
GATTTGACACATTT-3′; scramble control: 5′- TTCTC
CGAACGTGTCACGT-3′.
MYCN overexpression
MYCN expression vector (pCMV6-XL4-MYCN) was pur-
chased from (OriGene Technologies, Inc, USA). Plasmid
DNA was prepared from Endofree Plasmid Kit (Tiangen,
China) and transfected into NB cells through electropor-
ation (Nepa Gene, Japan). Cells were trypsinized and
resuspended in Opti-MEM (Life Technologies, USA). 10
μg DNA was mixed with 1×106 cells in a volume of 100μl
cells and placed into an electroporation cuvette. Place the
cuvette with cell-DNA mixture in the electroporation
holder. Set the electroporator at 150 V and pulse cells
twice with a pulse width of 5ms and an interval of 50ms.
After electroporation, cells were quickly transferred into a
pre-warmed culture plate containing media for the follow-
ing experiments.
Statistical analyses
Results were presented as means ± standard deviation
(SD). The significance of difference between groups was
determined by Student’s t-test.
Results
GANT-61 decreases cell viability and induce apoptosis in
MYCN amplified NB cells
GANT-61, an inhibitor of Hh signaling effector GLI
protein, was reported to have a cytotoxic effect on NB cell
lines, such as SK-N-AS, SH-SY5Y, SK-N-DZ etc., and
GANT-61 efficacy is reversely correlated with MYCN
expression [16]. To examine whether the reduced GANT-
61 sensitivity is a general phenomenon for MYCN ampli-
fied NB cells. We tested the effect of GANT-61 on two
other NB cell lines, NBL-W-S and SK-N-BE(2), which have
multiple-copy MYCN amplification (Figure 1A and
Additional file 1: Figure S1A). Using MTT assay, we exam-
ined the viability of NB cells under various concentrations
of GANT-61 (0.1-15 μM) at 48 h and 72 h after drug
treatment. The low concentrations of GANT-61 did not
substantially affect cell viability, while the higher con-
centrations of GANT-61 significantly reduced the num-
ber of NB cells. SK-N-BE(2) cells had fewer viable cells
at high concentration of GANT-61, with 11.52% live
cells at 72 h under 15 uM GANT-61, whereas NBL-W-S
cells had 34.43% live cells under the same condition.
The IC50 values of GANT-61 for NBL-W-S cells at 48 hand 72 h after treatment are 13.56 μM and 9.74 μM, re-
spectively (Figure 1B). Similar values were also achieved
for SK-N-BE(2) cells. The IC50 values of GANT-61 at
48 h and 72 h after treatment are 10.9 μM and 7.96 μM,
respectively (Additional file 1: Figure S1B). Both IC50
values at 72 h are similar to those reported for other
MYCN amplified NB cells [16], indicating that it is quite
a general rule for GANT-61 to have a lower cytotoxic
effect on MYCN amplified NB cells. Since 48 h treat-
ment of GANT-61 already had significant effect on both
cell lines, we used 48 h treatment of 10uM GANT-61 for
all the following experiments, if not indicated otherwise.
Previous studies have shown that cytotoxicity of
GANT-61 is mediated though apoptosis. Therefore, we
used Annexin V-FITC/PI double staining to evaluate
apoptotic status of NB cells after GANT-61 treatment.
Indeed, the number of apoptotic cells increased with the
concentration of GANT-61 in both NB cell lines
(Figure 1C and Additional file 1: Figure S1C). The sum
of early apoptotic cells (PI-/Annexin-FITC+) and late
apoptotic/necrotic cells went up to around 50% in both
cell lines (Figure 1C-1D and Additional file 1: Figure
S1C-1D). Interestingly, we noticed a small population of
necrotic cells existed even in untreated NB cells. How-
ever, the percentage of this population in the whole
population didn’t change too much with the increased
GANT-61 concentration.
To examine the biochemical changes in the GANT-61
induced apoptosis, we measured the expression of crit-
ical regulators of apoptotic process by Western blot.
GANT-61 significantly decreased the expression of
apoptotic regulator BCL2 and increased the level of ac-
tive CASPASE3 in both NB cell lines (Figure 1E and
Additional file 1: Figure S1E), suggesting the intrinsic
apoptotic pathway plays a major role in GANT-61 in-
duced apoptosis.GANT-61 induces autophagy in NB cells
Numerous studies have shown that autophagy has a
dual role in tumorigenesis, either functioning as a
tumor suppressor though removing aberrant proteins
and organelles, or as a mechanism maintaining cell sur-
vival under stress [17-19]. To understand whether au-
tophagy has a role in GANT-61 induced cell death, we
examined the formation of autophagic vacuoles with
MDC staining. MDC is an autofluorescent compound
that preferentially accumulates in mature autophagic
vacuoles, such as autophagolysosomes. As shown in
Figure 2A and Additional file 2: Figure S2A, we noticed
a gradual increase in the number and fluorescent intensity
of MDC-labeled vesicles with an increasing GANT-61 con-
centration in both NB cell lines. It suggests an induction of
autophagic vacuoles formation by GANT-61.
Figure 1 GANT-61 induces cell cytotoxicity and apoptosis in NB cells. (A) FISH analysis of MYCN amplification in NBL-W-S cells. Scale bar, 10μm. (B)
NBL-W-S cells were treated with GANT-61 at various concentration (0.1-15μM) for indicated times and the cytotoxicity was measured by MTT assay. The
percentage of viable cells was calculated as a ratio of treated to control cells. Data is expressed as the mean ± SD of three independent experiments.
*P < 0.05, **P < 0.01. (C) Representative flow cytometry analysis of apoptosis after Annexin V and PI-double staining. NBL-W-S cells were treated with the
indicated concentration of GANT-61 for 48h. (D) Histogram of flow cytometry analyses from 3 independent experiments. *P < 0.05, **P < 0.01. (E) Western
blot analysis was carried out to detect the expression of apoptosis-related proteins. NBL-W-S cells were treated with indicated concentrations of GANT-61
for 48h. The BCL2/β-ACTIN and Cleaved-CASPASE3/β-ACTIN ratios were determined by densitometry (mean ± SD), *P < 0.05, **P < 0.01. The expression of
anti-β-ACTIN is used as a loading control. CON, control.
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Figure 2 GANT-61 induces autophagy in NB cells. (A) MDC staining revealed that autophagy was activated in NBL-W-S cells after 48h
treatment with GANT-61. Scale bars, top: 100μm, bottom: 50μm. (B) Fluorescence microscopy of AO stained NBL-W-S cells treated with the
indicated drug for 48h. Top row, phase contrast images; Second row, images captured through green fluorescence filter; Third row, images
captured through red fluorescence filter; Bottom row, merged images. Scale bars, 100μm. (C) Flow cytometry analysis of AO stained cells in panel
B. (D) The expression of autophagic proteins in NBL-W-S cells treated with various concentrations of GANT-61 for 48h. The densitometry ratios of
LC3 II/β-ACTIN, ATG5/β-ACTIN and BECLIN1/β-ACTIN were plotted as histogram (mean ± SD), *P < 0.05. (E) Effect of lysosomal inhibitor BafA1 on
autophagic flux induced by GANT-61. LC3 immunoblotting was performed to evaluate LC3 conversion. NBL-W-S cells were first treated with
200nM BafA1 for 30 min and then treated with 10μM GANT-61 for 4h, 12h, 24h or 48h. The LC3 II/β-ACTIN ratio at different time points was
plotted as histogram (mean ± SD), *P < 0.05, **P < 0.01. (F) Immunofluorescence with LC3 antibody on NBL-W-S cells after 48h GANT-61 treatment.
Scale bars, top: 500μm, bottom: 20μm. CON, control. (G) Quantification of cells with a number of LC3 puncta five times higher than basal level in
panel F, **P < 0.01. (H) NBL-W-S cells transfected with GFP-LC3 plasmids were treated with GANT-61 for 48h. A puncta pattern of GFP-LC3 was
formed after drug treatment. Scale bar,20μm. (I) Quantification of cells with GFP-LC3 puncta in panel H, **P < 0.01. Equal loading and transfer
were verified by re-probing membranes with anti-β-ACTIN antibody in Western blot analysis.
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http://www.biomedcentral.com/1471-2407/14/768We further validated this finding with other assays. AO is
widely used for detection of AVOs, an indicator of autoph-
agy. In acid compartments, such as lysosomes and autoly-
sosomes, the fluorescence of AO switches from green to
red color. Consistent with MDC staining result, we ob-
served an increasing red fluorescence with the increasing
GANT-61 concentration, while control cells primarily ex-
hibited green fluorescence with minimal red fluorescence
(Figure 2B and Additional file 2: Figure S2B). Using flow cy-
tometry to do quantitative analysis, we observed five- and
two-fold increase of red fluorescent signal in NBL-W-S and
SK-N-BE(2) cells, respectively (Figure 2C and Additional
file 2: Figure S2C).
A symbolic marker of autophagosome formation is the
conversion of a soluble form of LC3-I to autophagic vesicle-
associated form LC3-II. We did note a significantly in-
creased LC3-II level after GANT61 treatment (Figure 2D
and Additional file 2: Figure S2D), suggesting an enhanced
autophagic induction with the increasing GANT-61 concen-
tration. Consistently, the level of BECLIN1, a critical compo-
nent for autophagosome initiation, significantly increased
with the increasing GANT-61concentration (Figure 2D and
Additional file 2: Figure S2D). The level of another autopha-
gosomal component ATG5 also significantly increased in
GANT-6-treated NBL-W-S cells (Figure 2D), though no sig-
nificant increase was observed in GANT-6-treated SK-N-BE
(2) cells (Additional file 2: Figure S2D).
To determine whether GANT-61 induces autophagic
production or disrupt autophagosomal consumption, we
applied a lysosomal proton pump inhibitor Bafilomycin
A1 (BafA1) to block the autophagosome-lysosome fusion
step. Cells were collected for anti-LC3 immunoblotting
at 4 h, 12 h, 24 h and 48 h after GANT-61 treatment.
From 12h on, cells treated with both GANT-61 and
BafA1 started to show a higher level of LC3-II than cells
treated with GANT-61 only (Figure 2E and Additional
file 2: Figure S2E), indicating that GANT-61 stimulates
autophagosomal production rather than autophagosomal
sysnthesis.
Autophagosomal formation was also visually examined
by immunofluorescence in both cell lines. GANT-61 sig-
nificantly increased endogenous LC3 puncta in both
MYCN amplified cell lines (Figure 2F-2G and Additional
file 2: Figure S2F-S2G). In addition, We transfected both
NBL-W-S and SK-N-BE(2) cells with GFP-LC3 plasmid
to monitor autophagic induction. After GANT-61 treat-
ment, we observed a distribution pattern change from a
homogenous distribution into punctuate dots in the
cytoplasm of a significant amount of cells (Figure 2H-2I
and Additional file 2: Figure S2H-S2I), indicating an in-
creased autophagosomal formation in these cells.
Overall, our fluorescent microscope and biochemical data
indicate that GANT-61 can induce autophagic induction in
MYCN amplified NB cells.Induced autophagy after GANT-61 treatment is
pro-survival
Having known autophagosome formation was enhanced
after GANT-61 treatment, we used autophagy inhibitor
3-MA to understand the role of autophagy in GANT-61
induced cell death. Incubation with 1mM 3-MA for 6h,
a treatment commonly used to inhibit autophagy in
cells, didn’t affect the viability of NB cell lines (Figure 3A
and Additional file 3: Figure S3A). However, it signifi-
cantly caused more cell death in GANT-61 treated cells
(Figure 3A and Additional file 3: Figure S3A), suggesting
a protective role of autophagy in GANT-61 induced cell
death. As expected, the inhibition of GANT-61 induced
autophagy by 3-MA pre-treatment was evidentiated by
the decreased levels of autophagosome markers LC3-II
and BECLIN 1 (Figure 3B and Additional file 3: Figure
S3B), possibly through a feedback elicited from autopha-
gic inhibition.
Since 3-MA is shown to have non-specific effects
other than autophagy inhibition in different cellular en-
vironments, such as inhibition of class I PI3K that could
lead to suppression of AKT phosphorylation [20], the in-
creased cell death caused by 3-MA pre-treatment might
be mediated through inhibition of AKT pro-survival
pathway instead of autophagy inhibition. To exclude this
possibility, we examined AKT phosphorylation at
30 min and 48 h after GANT-61 treatment. In our ex-
perimental condition, 3-MA pre-treatment didn’t change
the level of AKT phosphorylation in GANT-61 treated
cells at both time points (Figure 3C and Additional
file 3: Figure S3C). It suggests autophagic induction is
likely the major mechanism that MYCN amplified NB
cells use to resist the cytotoxicity of GANT-61.
To check whether the additional cell death was caused
by apoptosis, Annexin V-FITC/PI staining was applied to
quantitate apoptotic cells. Indeed, the combination of 3-
MA and GANT-61 increased the apoptotic cells from
52.78% and 54.11% up to 63.32% and 61.47% in NBL-W-S
and SK-N-BE(2) cell lines, respectively (Figure 3D and
Additional file 3: Figure S3D). Our data also showed a sig-
nificantly decreased level of BCL2 and an increased level
of cleaved CASPASE3 in 3-MA pre-treated NB cells lines
(Figure 3E and Additional file 3: Figure S3E), which again
suggested that an increased cell death induced by GANT-
61 in 3-MA pre-treated cells was caused by enhanced
apoptosis.
More specifically, we used a genetic approach to disrupt
the autophagic production. As shown in Figure 3F and
Additional file 3: Figure S3F, ATG5 or ATG7 shRNA specif-
ically knocked down ATG5 or ATG7 expression, respect-
ively. Knockdown of essential autophagic components
ATG5 or ATG7 completely abolished GANT-61 induced
LC3 conversion (Figure 3G and Additional file 3: Figure
S3G), indicating an autophagic inhibition. Similar to the
Figure 3 (See legend on next page.)
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Figure 3 Effects of autophagic inhibition on GANT-61 treated NB cells. (A) 3-MA pre-treatment enhanced GANT-61 toxicity on NBL-W-S cells. Cell
viability was measured by MTT assay. (B) The effect of 3-MA on the expression of autophagic proteins in NBL-W-S cells. Western blot analysis was
performed with anti-LC3, anti-BECLIN-1 and anti-ATG5 antibodies. The densitometry ratios of LC3 II/β-ACTIN, BECLIN1/β-ACTIN and ATG5/β-ACTIN were
plotted as histogram. (C) 3-MA pre-treatment did not affect the level of AKT phosphorylation in NBL-W-S cells after GANT-61 treatment. Values of P-AKT/
AKT ratio were listed under p-AKT blots. (D) 3-MA increased cell apoptosis in GANT-61 treated NBL-W-S cells. Apoptotic cells were analyzed using Annexin
V/PI double staining. (E) The effect of 3-MA on apoptotic protein expression. Western blot analysis was performed with anti-BCL-2 and anti-cleaved
CASPASE3 antibodies. The BCL2/β-ACTIN and Cleaved-CASPASE3/β-ACTIN ratios were listed under blots. (F) Knockdown of essential autophagic
component ATG5 or ATG7 by shRNA in NBL-W-S cells was verified by Western blot analysis with anti-ATG5 or anti-ATG7 antibodies. The ATG-5/β-ACTIN
and ATG-7/β-ACTIN ratios were listed under blots. (G) Knockdown of ATG5 or ATG7 completely abolished GANT-61 induced LC3 conversion, even in the
presence of lysosomal inhibitor BafA1. Knockdown cells were first treated with 200nM BafA1 for 30 min and then treated with 10μM GANT-61 for 12h. The
LC3 II/β-ACTIN ratio was listed under blots. (H) A higher level of cleaved CASPASE3 and a lower level of BCL2 were detected in ATG5 or ATG7 knockdown
NBL-W-S cells. The BCL2/β-ACTIN and cleaved-CASPASE3/β-ACTIN ratios were plotted as histogram. (I) Representative flow cytometry analysis of apoptosis
in GANT-61 treated cells. siCON: scramble shRNA knockdown control, siATG5: ATG5 shRNA knockdown, siATG7: ATG7 shRNA knockdown cells. CON,
control. Data are expressed as the mean ± SD, *P < 0.05, **P < 0.01, n.s., no statistical significance.
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http://www.biomedcentral.com/1471-2407/14/768effect of 3-MA pre-treatment, ATG5 knockdown decreased
the level of BCL2 and increased the level of cleaved CAS-
PASE3 in GANT-61 treated cells (Figure 3H and Additional
file 3: Figure S3H), suggesting an enhanced cell apoptosis
after autophagic inhibition. ATG7 knockdown in NBL-W-S
cells also showed a significant alteration in response to
GANT-61 treatment (Figure 3H), albeit a non-significant
change was observed in ATG7 knockdown SK-N-BE(2) cells
(Additional file 3: Figure S3H). Next, we used PE-Annexin
V/7-AAD double staining to quantitate apoptotic cell death
in GANT-61 treated shRNA knockdown cells. Indeed,
GANT-61 caused more apoptotic cell death in both ATG5
and ATG7 knockdown cells than those in scramble shRNA
knockdown cells (Figure 3I and Additional file 3:
Figure S3I). These date further confirmed that autoph-
agy is a protective mechanism preventing MYCN ampli-
fied NB cells from apoptotic cell death under the stress
of GANT-61.
Since autophagy could also be pro-death, we asked
whether inhibition of apoptosis in GANT-61 treated cells
could affect cell viability or not. We used Z-VAD-FMK, an
inhibitor of pan caspases, to suppress apoptotic pathway.
First, we tested the cytotoxicity of Z-VAD-FMK in both NB
cell lines and found no toxic effect in NBL-W-S and SK-N-
BE(2) at the concentration of 50μM (Figure 4A and
Additional file 4: Figure S4A). Therefore, we chose 50uM Z-
VAD-FMK for apoptotic inhibition experiment. We ob-
served that 50uM Z-VAD-FMK fully rescued cell viability
after GANT-61 treatment (Figure 4A and Additional file 4:
Figure S4A). A significantly increased level of BCL2 and a
significantly decreased level of cleaved CASPASE 3 were
also seen in Z-VAD-FMK treated cells (Figure 4B and
Additional file 4: Figure S4B), verifying the occurrence of
apoptotic inhibition. Interestingly, we noted that there was
no change in the level of LC3-II and BECLIN 1 after
addition of Z-VAD-FMK (Figure 4C and Additional file 4:
Figure S4C). AO staining also revealed similar amounts of
cells emitting red fluorescence between GANT-61 and
GANT-61 plus Z-VAD-FMK groups (Figure 4D andAdditional file 4: Figure S4D). Both indicate that apoptotic
inhibition doesn’t affect GANT-61 induced autophagic
process. These data again suggest that autophagy doesn’t
function as an alternative cell death pathway in GANT-61
treated cells. Instead, it is a pro-survival factor to prevent cell
death though apoptotic pathway triggered by GANT-61.
The level of GANT-61 induced autophagy is lower in
MYCN non-amplified NB cells
As MYCN non-amplified NB cells are more sensitive to
GANT61 [16], we hypothesized that it is due to a lower
level of the pro-survival autophagy induced in MYCN
non-amplified NB cells. First, we tested the efficacy of
GANT61 on SK-N-AS and SH-SY5Y cells, two known
MYCN non-amplified NB cell lines (Figure 5A). Using
MTT assay, we determined that the IC50 values of
GANT-61 on SK-N-AS cells at 48 h and 72 h after drug
treatment are 7.54 μM and 6.12 μM, respectively, and
those on SH-SY5Y cells are 8.83 μM and 6.96 μM, re-
spectively (Figure 5B). They are lower than the IC50
values of GANT-61 on NBL-W-S and SK-N-BE(2)
(Figure 1A and Additional file 1: Figure S1A). It con-
firmed that MYCN non-amplified NB cells are more
sensitive to GANT-61. Next, we examined the autopha-
gic flux on these two MYCN non-amplified NB cell
lines. Indeed, GANT-61 didn’t induce as much LC3
conversion in these two cell lines as it did in two MYCN
amplified NB cell lines, even with the presence of
lysosomal inhibitor BafA (Figure 5C, Figure 2E and
Additional file 2: Figure S2E). It indicates that GANT-
61 can’t enhance autophagic induction in GANT-61
treated MYCN non-amplified cells. Furthermore, we
used AO for AVOs staining to evaluate the level of au-
tophagy. Consistent with Western blotting results, we
observed a weaker red fluorescence in both MYCN
non-amplified cells (Figure 5D). Flow cytometry analysis
quantitatively showed that the intensity of red fluores-
cence is much lower in both MYCN non-amplified cells
than those in MYCN amplified cells (Figure 5E),
Figure 4 Effects of an apoptotic inhibitor on GANT-61 treated NB cells. (A) NBL-W-S cells were pre-treated with Z-VAD-FMK (50 μM) for 1h
and then with 10uM GANT-61 for 48 h. Cell viability was measured by MTT assay. Data are expressed as the mean ± SD of three independent
experiments. *P < 0.05. (B) The inhibitory effects of Z-VAD-FMK on apoptosis were detected by Western blot analysis with anti-BCL-2 and
anti-cleaved CASPASE3 antibodies. The BCL2/β-ACTIN and cleaved-CASPASE3/β-ACTIN ratios were listed under blots (mean ± SD), *P < 0.05.
(C) The expression of autophagic proteins was analyzed by Western blot with anti-LC3 and anti-BECLIN-1 antibodies. The densitometry ratios of
LC3 II/β-ACTIN and BECLIN1/β-ACTIN were listed under blots, (mean ± SD), *P < 0.05, n.s., no statistical significance. (D) Flow cytometry histogram
of AO stained cells treated with the indicated drug. CON, control. Equal loading and transfer were verified by re-probing membranes with anti-β-ACTIN
antibody in Western blot analysis.
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amplified cells. To recapitulate MYCN amplification in
these MYCN non-amplified cells, we overexpressed
MYCN in SK-N-AS and SH-SY5Y cells through electro-
poration (Figure 5F). It significantly enhanced autophagic
production induced by GANT-61 (Figure 5G), demon-
strating that MYCN amplification is a positive factor in
GANT-61 induced protective autophagy.Discussion
NB is a common extra cranial tumor in childhood. Ab-
errant Hh signaling has recently been found associated
with NB. Hh signaling inhibitors could suppress tumor
growth through apoptotic induction [14,16,21]. Among
them, GANT-61, a small molecular inhibitor of Hh
signaling effector Gli, induces considerably greater cytotox-
icity in NB cell lines than inhibitors of Hh signaling
Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 GANT-61 induces a lower level of autophagy in MYCN non-amplified NB cells. (A) FISH analysis of MYCN copy number in SK-N-AS
and SH-SY5Y cells. White arrows indicate positive signals. Scale bars, 10μm. (B) SK-N-AS and SH-SY5Y cells were treated with GANT-61 at various
concentration (0.1-15μM) for indicated times and the cytotoxicity was measured using a MTT assay. The percentage of viable cells was calculated as a
ratio of treated to control cells. (C) The effect of lysosomal inhibitor BafA1 on LC3 conversion in SK-N-AS and SH-SY5Y cells treated with GANT-61. Cells
were first treated with 200nM BafA1 for 30 min and then treated with 10μM GANT-61 for 12h. The LC3 II/β-ACTIN ratio was listed under blots. (D)
Fluorescence microscopy of AO stained SK-N-AS, SH-SY5Y, NBL-W-S and NBL-W-S cells treated with 10μM GANT61 for 48h. Top row, phase contrast;
Second row, green fluorescence; Third row, red fluorescence; Bottom row, merged images. Scale bars, 100μm. (E) Flow cytometry histograms of AO
stained NB cells. The last plot summarizes four histogram profiles to visualize the difference of fluorescence intensities in MYCN non-amplified and
amplified NB cells. (F) MYCN overexpression was verified by Western blot analysis with SK-N-AS and SH-SY5Y cells transfected with MYCN plasmid. The
MYCN/β-ACTIN ratio was listed under blots. (G) The effect of lysosomal inhibitor BafA1 on LC3 conversion in SK-N-AS/MYCN and SH-SY5Y/MYCN cells
treated with GANT-61. Cells were first treated with 200nM BafA1 for 30 min and then treated with 10μM GANT-61 for 12h. SK-N-AS/MYCN: SK-N-AS
cells overexpressing MYCN. SH-SY5Y/MYCN: SH-SY5Y cells overexpressing MYCN. Equal loading and transfer were verified by re-probing membranes
with anti-β-actin antibody. The LC3 II/β-ACTIN ratio was listed under blots. Data is expressed as the mean ± SD. *P < 0.05, **P < 0.01.
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http://www.biomedcentral.com/1471-2407/14/768receptor Smo do. However, MYCN amplified NB cells are
less susceptible to GANT-61 than MYCN non-amplified
NB cells are [16]. We confirmed this observation with two
additional MYCN amplified NB cell lines. MYCN amplifi-
cation is so far the most reliable prognostic factor for high-
risk NB [22,23]. Our new findings reiterate clinical
outcomes of high-risk NB with MYCN amplification.
MYCN is a transcription factor belonging to the MYC
family of proto-oncogene, which regulates critical cellular
processes including proliferation, cell growth and differen-
tiation [24]. MYCN amplification is considered as an
oncogenic driver of aggressive NB and MYCN targeted
therapies have shown promises for treating this subset NB
[25,26]. Although numerous studies have focused on dis-
secting the molecular mechanism underlying MYCN-
mediated resistance, a lot still remain to be discovered.
To understand the possible mechanism of GANT-61
resistance in MYCN amplified NB cell lines, we examined
autophagic process in GANT-61 treated NB cells due to a
role of MYC proteins in autophagic induction to promote
cell survival [27]. Autophagy is a lysosome-dependent de-
gradative pathway that is often induced under cell stress
conditions to catabolize cytoplasmic contents [28-30]. It re-
mains disputable whether therapy-induced autophagy in
cancer cells is a self-defense mechanism to maintain cell
survival or a non-apoptotic form of programmed cell death.
Our data showed that GANT-61 could enhance autopha-
gosomal formation in NB cells (Figure 2E and Additional
file 2: Figure S2E), presenting an increasing number of
AVOs stained by AO or MDC with an increasing drug
concentration (Figure 2A-2C and Additional file 2: Figure
S2A-S2C). Likewise, it was further evidentiated by increases
in LC3-II levels and other autophagy-related molecules in
GANT-61 treated NB cells (Figure 2D and additinoal
Figure 2D). Consistently, activation of Shh signaling was
shown to have a conserved role in suppressing autophago-
somal synthesis from drosophila up to human, and both in
normal and malignant cells, whereas inhibition of Shh sig-
naling could increase autophagy [31,32].To understand the role of autophagy in GANT-61
induced cell death, autophagic formation was inhibited
by 3-MA. We observed a significant increase of apop-
totic cells after GANT-61 treatment (Figure 3D-3E and
Additional file 3: Figure S3D-S3E). Using genetic ap-
proach, we confirmed this finding through knockdown
of essential autophagic components ATG5 and ATG7
(Figure 3G-3I and Additional file 3: Figure S3G-S3I).
These data demonstrate that autophagy induced by
GANT-61 is indeed a protective factor in NB cells. Both
GANT-61 and cyclopamine are small molecules inhibit-
ing Hh signaling. But NB cells are more ressistant to
cyclopamine [16]. Given the protective role of drug-
induced autophage we showed here, cyclopamine resist-
ance might be explained by a stronger autophagic
induction, because it is shown that cyclopamine could
not only increase autophagosomal synthesis through
Smo acitivity inhibition, but also impair autophagoso-
mal degradation through an unknow mechanism [31].
From the opposite end to approach this question, we
inhibited apoptosis with Z-VAD-FMK. Inhibition of apop-
tosis rescued GANT-61 induced cell death, while no en-
hancement of autophagosomal formation was observed
(Figure 4C and Additional file 4: Figure S4C). It indicates
that GANT-61 induced autophagy is independent of cellu-
lar apoptotic process and is not a programmed cell death
alternative to apoptosis.
It has been shown that both C-Myc and N-Myc over-
expression are capable of inducing cytoprotective
autophagy [27]. Several studies have also shown that tu-
mors with high MYC expression activate autophagy to
promote cell survival under drug treatment [32,33].
Consistently, our results showed that GANT-61 treat-
ment hardly induced LC3 conversion in MYCN non-
amplified cells (Figure 5C). Ao staining showed much
lower levels of red fluorescent autophagosome in
GANT-61 treated MYCN non-amplified NB cells than
those in GANT-61 treated MYCN amplified NB cells
(Figure 5D), indicating that MYCN amplification is
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NB cells. Overexpression of MYCN in MYCN non-
amplified NB cells indeed reiterate GANT-61 induced
autophagy seen in MYCN amplified NB cells, which
suggests that MYCN amplification could render NB
cells the capability to resist GANT-61 toxicity through
induction of pro-survival autophagy.Conclusions
Overall, our data revealed the existence of a protective au-
tophagy in GANT-61 treated NB cells. The level of the
pro-survival autophagy is related to MYCN expression
level. Inhibition of autophagy in MYCN amplified NB cells
could augment the efficacy of GANT-61 on MYCN ampli-
fied NB cells. It partially explains the GANT-61 resistance
in MYCN amplified NB cells and suggests that a combin-
ation of GANT-61 and autophagic inhibitor could be a
good approach to treat MYCN amplified NB. However, the
molecular mechanism how MYCN amplification is in-
volved in drug-induced autophagy remains to be answered.Additional files
Additional file 1: Figure S1. GANT-61 induces cell cytotoxicity and
apoptosis in NB cells. (A) MYCN amplification was evaluated by FISH
analysis in SK-N-BE(2) cells. Scale bars, 10μm. (B) GANT-61 dosage
response curves of SK-N-BE(2) cells were determined using a MTT assay.
The percentage of viable cells was calculated as a ratio of treated to
control cells. Data is expressed as the mean ± SD of three independent
experiments. *P < 0.05, **P < 0.01. (C) Flow cytometry analysis of
apoptosis after AnnexinV and PI-double staining SK-N-BE(2) cells were
treated with indicated concentration of GANT-61 for 48h. (D) Histogram
of flow cytometry analyses from 3 independent experiments. *P < 0.05,
**P < 0.01, CON, control. (E) Western blot analysis was performed to
detect the expression of apoptosis-related proteins. SK-N-BE(2) cells were
treated with indicated concentration of GANT-61 for 48h. The BCL2/β-ACTIN
and Cleaved-CASPASE3/β-ACTIN ratios were determined by densitometry
(mean ± SD), *P < 0.05, **P < 0.01. Equal loading and transfer were verified by
re-probing membranes with anti-β-ACTIN antibody. CON, control.
Additional file 2: Figure S2 GANT-61 induces autophagy in NB cells.
(A) MDC staining showed that the autophagy was activated in SK-N-BE(2)
cells after GANT-61 treatment for 48h. Scale bars, top: 100μm, bottom:
50 μm. (B) Fluorescence microscopy of AO stained SK-N-BE(2) cells
treated with the indicated concentration of GANT-61. Scale bars, 100μm.
(C) Flow cytometry analysis of AO stained cells in panel B. (D) The expression
of autophagic proteins in GANT-61 treated SK-N-BE(2) cells. The densitometry
ratios of LC3 II/β-ACTIN, ATG5/β-ACTIN and BECLIN1/β-ACTIN were plotted as
histogram (mean ± SD), *P < 0.05, **P < 0.01. (E) Effect of lysosomal inhibitor
BafA1 on autophagic flux induced by GANT-61. SK-N-BE(2) cells were first
treated with 200nM BafA1 for 30 min and then treated with 10μM GANT-61
for 4 h, 12 h, 24 h or 48 h. The LC3 II/β-ACTIN ratio at different time
points was plotted as histogram (mean ± SD), *P < 0.05, **P < 0.01. (F)
Immunofluorescence with LC3 antibody on SK-N-BE(2) cells after 48h
GANT-61 treatment. Scale bars, top: 500μm, bottom: 20μm. CON, control.
(G) Quantification of cells with a number of LC3 puncta five times
higher than basal level in panel F. **P < 0.01 (H) SK-N-BE(2) transfected
with GFP-LC3 plasmids were treated with GANT-61 for 48h. A puncta
pattern of GFP-LC3 was formed after drug treatment. Scale bar,20 μm.
(I) Quantification of cells with GFP-LC3 puncta shown in panel H,
**P < 0.01. Equal loading and transfer were verified by re-probing
membranes with anti-β-ACTIN antibody in Western blot analysis.Additional file 3: Figure S3. Effects of autophagic inhibition on GANT-61
treated NB cells. (A) The effect of 3-MA on SK-N-BE(2) cell viability. Cell viability
was measured by MTT assay. (B) Effect of 3-MA on autophagic proteins in
SK-N-BE(2) cells. Western blot analysis was performed with anti-LC3,
anti-BECLIN-1 and anti-ATG5 antibodies. The densitometry ratios of LC3
II/β-ACTIN, BECLIN1/β-ACTIN and ATG5/β-ACTIN were plotted as histogram.
(C) Effect of 3-MA on AKT phosphorylation was examined by Western blot in
SK-N-BE(2) cells treated with GANT-61. Values of P-AKT/AKT ratio were listed
under p-AKT blots. (D) Effect of 3-MA on cell apoptosis. SK-N-BE(2) cells were
treated with GANT-61 and 3-MA at the indicated concentration for 48 h.
Apoptotic cells were quantitated by flow cytometry. (E) The effect of 3-MA on
apoptotic protein expression. Western blot analysis was performed with
anti-BCL-2 and anti-cleaved CASPASE3 antibodies. The BCL2/β-ACTIN and
Cleaved-CASPASE3/β-ACTIN ratios were listed under blots. (F) ATG5 or ATG7
shRNA specifically knocked down ATG5 or ATG7, respectively, in SK-N-BE(2) cells.
Western blot analysis was performed with anti-ATG5 and anti-ATG7 antibodies.
The ATG-5/β-ACTIN and ATG-7/β-ACTIN ratios were listed under blots. (G)
Knockdown of essential autophagic components ATG5 or ATG7 completely
abolished GANT-61 induced autophagic production. The LC3 II/β-ACTIN ratio
was listed under blots. (H) GANT61 caused a higher level of cleaved CASPASE3
and a lower level of BCL2 in ATG5 or ATG7 knockdown NB cells than those in
scramble shRNA knockdown controls. The BCL2/β-ACTIN and cleaved-
CASPASE3/β-ACTIN ratios were plotted as histogram. (I) Representative flow
cytometry analysis of apoptosis in GANT-61 treated cells after PE-AnnexinV and
7-AAD double staining. siCON: scramble shRNA control, siATG5: ATG5 shRNA
knockdown, siATG7: ATG7 shRNA knockdown. CON, control. Data are expressed
as the mean ± SD. *P < 0.05,**P < 0.01, n.s., no statistical significance.
Additional file 4: Figure S4. Effects of an apoptotic inhibitor on
GANT-61 treated NB cells. (A) The effect of Z-VAD-FMK on SK-N-BE(2) cell
viability. Cell viability was measured by MTT assay. Data are expressed as
the mean ± SD of three independent experiments. *P < 0.05. (B) Western
blot analysis was performed with anti-BCL-2 and anti-cleaved CASPASE3
antibodies. The BCL2/β-ACTIN and cleaved-CASPASE3/β-ACTIN ratios
were listed under blots (mean ± SD), *P < 0.05. (C) Western blot analysis
was performed with anti-LC3, anti-BECLIN-1 antibodies. The densitometry
ratios of LC3 II/β-ACTIN and BECLIN1/β-ACTIN were listed under blots,
(mean ± SD), *P < 0.05, n.s., no statistical significance. (D) Flow cytometry
histogram of AO stained SK-N-BE(2) cells treated with the indicated drug.
Con, control. Equal loading and transfer were verified by re-probing
membranes with anti-β-ACTIN antibody in Western blot analysis. CON,
control.
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